Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
- PMID: 17308264
- DOI: 10.1200/JCO.2006.09.3542
Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
Comment on
-
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2007 Feb 20;25(6):625-33. doi: 10.1200/JCO.2006.06.4220. J Clin Oncol. 2007. PMID: 17308267
-
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.J Clin Oncol. 2007 Feb 20;25(6):634-41. doi: 10.1200/JCO.2006.06.3081. J Clin Oncol. 2007. PMID: 17308268
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
